Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma

Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news